Diuretic efficacy of torasemide in nephrotic syndrome: bolus injection versus continuous infusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006391

Enrollment

Unknown

Registered

2015-05-15

Start date

2015-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotic syndrome

Interventions

2:torasemide bolus then infusion

1:torasemide infusion after bolus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. diagnosis of nephritic syndrome (24-hour urine albumin> 3.5 g and serum albumin concentration <30 g/liter); 2. Aged 18 to 70 years; 3. need of diuretic treatment; 4. provid written informed consent.

Exclusion criteria

Exclusion criteria: 1. hypotension, defined as blood pressure 40 U/liter; 6. serum K+ 5.5mmol/L; 7. serum Na+ 145mmol/L; 8. vomit; 9. diarrhoea; 10. fever; 11. polypnea; 12. open skin injury area >5% body surface area; 13. deep vein thrombosis.

Design outcomes

Primary

Measure	Time frame
urinary volume;urinary sodium excretion;urinary chloride excretion;24-hourtorasemide excretion;	—

Countries

China

Contacts

Public ContactWenjian Wang

Guangdong General Hospital, Guangdong Academy of Medical Science

wwjph@126.com+86 13928985527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026